CeriBell stock
CBLLNASDAQCeriBell, Inc., HealthcareISIN US15678C1027
49Score 49 out of 100, Weak
Price and trend
83 / 100
Price history
+105% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 25% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 6.8% below its 52-week high. Largest decline in 2 years: 64% (December 2024 to November 2025).
Chart figures for advanced users
- SMA 50$25.49
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$21.01
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.49
- The lowest closing price of the last twelve months.
- Resistance$28.27
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- CeriBell, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $1.02B, is number 58 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $89.06M (up 36.1% year on year) and a loss of $53.41M.
- For fiscal 2026, analysts expect on average revenue of $115.62M (up 29.8%) and adjusted earnings per share of −$2.02.
Show more
- MEQIRI Score 49 out of 100 (Weak): rank 391 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 50.9% a year since 2022, Medical (Devices) median 13.8%.Growth 70
- More cash than debtCash $117.47M, financial debt $21.65M.Stability 57
Weaknesses
- DilutionShare count up 57% since 2022.Capital allocation 18
- Loss-makingLoss of $73.88M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$58.7M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 31.3% on the twelve months before. Revenue has grown strongly since 2022, at around 51% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 88%, operating −66%, net −60%. Last 12 months: net −68%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Feb 2027in 103 days
- Last reported
- 3 Nov 2026EPS reported −$0.55 (expected −$0.51)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 4.8% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$2.02−2.3%
- Revenue
- $115.62M+0.1%
- Earnings per share
- −$1.68−4.8%
- Revenue
- $147.36M+0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +13.3%2026 revenue guidance raised to $114 to $117 million from $112 to $116 million (growth of 28% to 31%).
“We expect full year 2026 total revenue to range from $114 million to $117 million up from our prior guidance of $112 million to $116 million This represents annual growth of 28% to 31% over 2025.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 10 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 8 insiders sold, $10.78M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Taylor Joseph MichaelSale
9 Nov 2026, Board
- Shares
- 10,200
- Price
- $27.22
- Value
- $277,644
- Woo RaymondSale
2 Nov 2026, Chief Technology Officer
- Shares
- 4,887
- Price
- $26.96
- Value
- $131,754
- Woo RaymondSale
1 Oct 2026, Chief Technology Officer
- Shares
- 4,887
- Price
- $24.38
- Value
- $119,145
Show 29 more
- Chao XingjuanSale
15 Sept 2026, President and CEO
- Shares
- 20,846
- Price
- $25.03
- Value
- $521,775
- Blumberg ScottSale
15 Sept 2026, Chief Financial Officer
- Shares
- 846
- Price
- $25.00
- Value
- $21,150
- Foehr DavidSale
8 Sept 2026, Senior VP, Finance and PAO
- Shares
- 9,255
- Price
- $24.25
- Value
- $224,451
- Woo RaymondSale
8 Sept 2026, Chief Technology Officer
- Shares
- 4,887
- Price
- $24.33
- Value
- $118,901
- Chao XingjuanSale
2 Sept 2026, President and CEO
- Shares
- 39,540
- Price
- $24.61
- Value
- $973,079
- Blumberg ScottSale
2 Sept 2026, Chief Financial Officer
- Shares
- 652
- Price
- $25.00
- Value
- $16,300
- Foehr DavidSale
24 Aug 2026, Senior VP, Finance and PAO
- Shares
- 859
- Price
- $23.95
- Value
- $20,573
- Manni Joseph S.Sale
21 Aug 2026, Chief Revenue Officer
- Shares
- 1,361
- Price
- $24.02
- Value
- $32,691
- Foehr DavidSale
21 Aug 2026, Senior VP, Finance and PAO
- Shares
- 993
- Price
- $24.02
- Value
- $23,852
- Woo RaymondSale
21 Aug 2026, Chief Technology Officer
- Shares
- 1,979
- Price
- $24.02
- Value
- $47,536
- Blumberg ScottSale
21 Aug 2026, Chief Financial Officer
- Shares
- 1,521
- Price
- $24.02
- Value
- $36,534
- Chao XingjuanSale
21 Aug 2026, President and CEO
- Shares
- 6,068
- Price
- $24.02
- Value
- $145,753
- Blumberg ScottSale
19 Aug 2026, Chief Financial Officer
- Shares
- 33,512
- Price
- $25.03
- Value
- $838,805
- Chao XingjuanSale
19 Aug 2026, President and CEO
- Shares
- 31,415
- Price
- $25.03
- Value
- $786,317
- Blumberg ScottSale
18 Aug 2026, Chief Financial Officer
- Shares
- 990
- Price
- $25.00
- Value
- $24,750
- Chao XingjuanSale
18 Aug 2026, President and CEO
- Shares
- 2,199
- Price
- $25.00
- Value
- $54,975
- Taylor Joseph MichaelSale
13 Aug 2026, Board
- Shares
- 13,095
- Price
- $23.40
- Value
- $306,423
- Chao XingjuanSale
3 Aug 2026, President and CEO
- Shares
- 39,000
- Price
- $18.32
- Value
- $714,480
- Chao XingjuanSale
7 Jul 2026, President and CEO
- Shares
- 23,554
- Price
- $19.90
- Value
- $468,725
- Burke William WSale
30 Jun 2026, Board
- Shares
- 2,207
- Price
- $19.84
- Value
- $43,787
- Tpg Gp A, LlcSale
26 Jun 2026, Major holder
- Shares
- 202,368
- Price
- $20.12
- Value
- $4.07M
- Taylor Joseph MichaelSale
11 Jun 2026, Board
- Shares
- 5,500
- Price
- $18.41
- Value
- $101,255
- Chao XingjuanSale
8 Jun 2026, President and CEO
- Shares
- 23,554
- Price
- $18.33
- Value
- $431,745
- Foehr DavidSale
22 May 2026, Senior VP, Finance and PAO
- Shares
- 862
- Price
- $18.80
- Value
- $16,206
- Manni Joseph S.Sale
21 May 2026, Chief Revenue Officer
- Shares
- 1,378
- Price
- $18.00
- Value
- $24,804
- Foehr DavidSale
21 May 2026, Senior VP, Finance and PAO
- Shares
- 987
- Price
- $18.00
- Value
- $17,766
- Woo RaymondSale
21 May 2026, Chief Technology Officer
- Shares
- 1,966
- Price
- $18.00
- Value
- $35,388
- Blumberg ScottSale
21 May 2026, Chief Financial Officer
- Shares
- 1,387
- Price
- $18.00
- Value
- $24,966
- Chao XingjuanSale
21 May 2026, President and CEO
- Shares
- 6,030
- Price
- $18.00
- Value
- $108,540
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at CeriBell
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 49
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Integra LifeSciences HoldingsIART $1.15B50
- Alphatec HoldingsATEC $1.14B34
- SI-BONESIBN $1.13B47
- IRadimedIRMD $1.11B77
- AdaptHealthAHCO $1.06B33
- ArtivionAORT $980M32
- Kuros BiosciencesKURN.SW $962.93M47
- OrthoPediatricsKIDS $879.14M47
ETFs that hold CeriBell
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 5 Nov 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.